Teduglutide: A Review in Short Bowel Syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0703-7
Abstract: Subcutaneous teduglutide (Revestive®), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged ≥1 year who are stable following a period of… read more here.
Keywords: teduglutide review; review short; short bowel; bowel syndrome ... See more keywords